europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

Joint Statement on the Health Innovation Partnership Proposal

03/08/2020
POSITION PAPER
Joint Statement on the Health Innovation Partnership Proposal

Joint Statement on the Health Innovation Partnership Proposal

Health industry sectors, representing pharmaceutical and medical technology companies (COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe) welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.

A future for collaborative research & development in Europe

The future partnership will showcase to researchers, patients, and citizens that Europe has the ambition to be a world-leader in collaborative research and development (R&D). It will pioneer the patient-centred integration of knowledge, technology and products to address the entire care continuum for the benefit of patients across Europe and beyond.

Investment in collaborative R&D can play a significant role in building health resilience, improving European health systems’ sustainability, addressing the needs of patients across Europe, and driving the region’s economic recovery from the COVID-19 crisis. The pandemic has also underlined the importance of having a large-scale partnership for health innovation to mobilise and coordinate public and private research efforts aimed at tackling global public health threats.

Insights into an ambitious and pioneering public-private proposal

The life-science sector partners and the European Commission describe the new partnership's objectives, deliverables, governance and operational model in the Partnership Proposal. While the proposal will be subject to further discussion, the document already gives an insight into the specific elements that will be addressed in the draft partnership legislation expected in Autumn 2020.

All partners are dedicated to developing new solutions for patients, healthcare professionals and systems, as well as their implementation in research and health practice in different socio-economic conditions across Europe. Impactful solutions for public health and sustainable healthcare systems have always been and will remain at the core of our industries’ mission. This endeavour will guide the work of scientists and researchers collaborating under the new health innovation partnership. The partners fully support the European Commission in its efforts to provide a harmonised set of rules for institutionalised partnerships while, at the same time, ensuring efficient processes and flexibility for crosssectorial collaboration.

Opening new spaces for impactful synergies

For a thriving European research ecosystem, this new partnership will create synergies and complement other features of the European research landscape, in particular with the EUAfrica Global Health Partnership, potential co-funded Partnerships on ‘Health and Care Systems Transformation’, the European Partnership for One Health/AMR and ‘Pandemic Preparedness and Societal Resilience’, and with the EU4Health Programme.

Download the file below to read the full Position Paper.

Joint Statement on the Health Innovation Partnership Proposal


Download
2020_08_H_PP_Health-Innovation-PPP-Proposal-Joint-StatementDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more
19/12/2022

The Association of Biotechnological Companies Bioforum joins EuropaBio: representing Polish biotech at European legislative fora and involving Polish companies in the debate about the future of the industry


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member